FSRH Annual Review 2018
... two new FSRH Clinical Guidance documents, supporting members to provide effective SRH care • Drug Interactions with Hormonal Contraception • Contraception for Women Aged over 40 Generated a 101% ...
GMC Generic Professional Capabilities Framework
... neonates, children and older people with frailty assess a clinical situation to recognise a drug reaction manage adverse incidents,* therapeutic interactions and report adverse drug reactions ...
Membership Exam Part I Handbook (MFSRH)
... only D. It is considered safe to use in pregnant women E. Methemoglobinemia never occurs with this drug MFSRH Part I Handbook Last Reviewed: May 2023 Page 8 of 34 CiP 4 Data 4. In order to allocate staff ...
CSRH Guide to CiP 1
... blood products and fluids correctly, accurately and unambiguously and with due regard to relevant drug interactions in accordance with GMC and other guidance. • Determines responsibility for follow up, ...
FSRH New Product Review: Jaydess® Levonorgestrel Intrauterine System LNG IUS (April 2014)
... outweigh the risks). There are no restrictions on use of LNG-IUS in nulliparous women. Are there any drug interactions? Theoretically, because Jaydess and Mirena contain the same contraceptive hormone and ...
Membership Exam Part II Handbook (MFSRH)
Privacy notice We would like to set cookies on your device as described in our cookie policy . If you're OK with this then please accept and continue. Alternatively you can control which cookies are ...
MedFASH Press Release HIV in Primary Care 2016
... HIV specialist care practice policies and systems a quick reference guide to antiretrovirals, drug interactions and side effects, managing HIV- related problems, information for patients and a list ...
FSRH CEU response to public consultation comments POP Guideline
... and blood pressure, for example”. This is early in guidance and risks conversion to a guidance and drug promotion point. Suggestion indicate that it is below a level D and not yet good practice Amended in ...
FSRH CEU new product review: Drovelis® estetrol/drospirenone combined oral contraceptive (October 2022)
... European/Russian phase III study[4], 9.1% discontinued because of apparent side effects of E4/DRSP. Drug interaction Key information: As with other CHC, the contraceptive effectiveness of E4/DRSP could be ...
Emergency Contraception Response to Consultation - March 2017
... and double dosing, Contraception. 2016; 94(1):52-57. Jusko W.J. Clarification of contraceptive drug pharmacokinetics in obesity, Contraception. 2017; 95(1):10-16. Cherala G., Edelman A., Dorflinger ...